# hC Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hc-bioscience

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.hcbioscience.com
- Total disclosed funding: $20M
- Latest round: Series A (Feb 28, 2023)
- Investors on record: 6

## About

Founded in 2021 by CEO Leslie J. Williams, and based in Massachusetts, US, hC Bioscience, Inc. operates as a biotechnology company that develops and discovers tRNA (Transfer RNA) therapy for protein diseases. In February 2023, hC Bioscience, Inc. raised an undisclosed amount of series A funding from new investor CureDuchenne Ventures.

The company develops engineered tRNAs to overcome disease-causing issues in the genetic code as proteins are made. The company's PTCX (“Patch”) platform uses engineered tRNAs to recognize nonsense mutations in mRNA transcripts and suppresses them by inserting an amino acid where it is needed, restoring the protein to full length and function. The company is also developing a second tRNA-based platform called SWTX (“Switch”) to target diseases caused by missense mutations. 

The company plans to use the Series A funding to develop an innovative pipeline of protein-editing therapies.

## Funding rounds

- Series A, Feb 28, 2023 — CureDuchenne Ventures
- Series A, Nov 1, 2022, $8M — ARCH Venture Partners, Takeda Ventures, 8VC, Taiho Ventures, Panacea Venture
- Series A, Dec 3, 2021, $12M — ARCH Venture Partners, Takeda Ventures, 8VC

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A
- 8VC (https://capitalatlas.ai/funds/8vc) — Series A
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Series A
- Panacea Venture (https://capitalatlas.ai/funds/panacea-venture) — Series A
- CureDuchenne Ventures (https://capitalatlas.ai/funds/cureduchenne-ventures) — Series A